Mpro |
Main protease |
SARS |
Severe acute respiratory syndrome |
COVID-19 |
Coronavirus disease 2019 |
SARS-CoV-2 |
Severe acute respiratory syndrome coronavirus 2 |
CoVs |
Coronaviruses |
HCoV-NL63 |
Human coronavirus NL63 |
HCoV-229E |
Human coronavirus 229E |
HCoV-OC43 |
Human coronavirus OC43 |
HCoV-HKU1 |
Human coronavirus HKU1 |
SARS-CoV |
Severe acute respiratory syndrome coronavirus |
MERS-CoV |
Middle East respiratory syndrome coronavirus |
ORFs |
Open reading frames |
3CLpro |
Chymotrypsin-like cysteine protease |
S |
Spike surface glycoprotein |
E |
Small envelope protein |
M |
Matrix protein |
N |
Nucleocapsid protein |
N3(PRD_002214) |
N-[(5 methylisoxazol-3-yl)carbonyl] alanyl-L-valyl-N~1-((1R,2Z)-4-(benzyloxy)-4-oxo-1-{[(3R)-2-oxopyrrolidin-3-yl]methyl}but-2-enyl)-L-leucinamide |
cMD |
Classical molecular dynamics simulations |
MixMD |
Mixed-solvent molecular dynamics simulations |
PDB |
Protein Data Bank |
MAV |
Maximal accessible volume |
ACN |
Acetonitrile |
BNZ |
Benzene |
DMSO |
Dimethylsulfoxide |
MEO |
Methanol |
PHN |
Phenol |
URE |
Urea |
CMA |
Correlated mutation analysis |
FDA |
Food and Drug Administration |